Skip to main
ARAY

Accuray (ARAY) Stock Forecast & Price Target

Accuray (ARAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Accuray is a radiation oncology company with a unique and innovative technology, the CyberKnife, that allows for precise and high-dose radiation treatment for various types of cancer. This positions them well in the growing market for cancer treatments, which is expected to reach $220 billion by 2025. Despite facing challenges with market uncertainty and macroeconomic conditions, the company has been able to maintain a solid financial position, with a strong balance sheet and a lower EV/Sales multiple compared to its peers. As such, while maintaining a cautious stance, our outlook for Accuray's stock remains positive.

Bears say

Accuray is facing multiple challenges currently, including geopolitical uncertainty and macroeconomic factors beyond their control, which have led to delays in revenue recognition and a decline in commercial execution. Despite cost-cutting efforts, the company has missed its financial guidance and is facing declining revenue and profitability. With multiple contracting across the MedTech sector and little visibility on a turnaround, it is unlikely that investors will have an appetite for Accuray's stock.

Accuray (ARAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Accuray (ARAY) Forecast

Analysts have given Accuray (ARAY) a Buy based on their latest research and market trends.

According to 2 analysts, Accuray (ARAY) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Accuray (ARAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.